Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. We show 28 historical shares outstanding datapoints in our ALRN shares outstanding history coverage, used to compute ALRN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALRN market cap history over the course of time is important for investors
interested in comparing ALRN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALRN versus a peer is one thing; comparing
ALRN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALRN can fluctuate over the course of history.
With this page we aim to empower investors researching ALRN by allowing them to research the ALRN market cap history. |
Free ALRN Email Alerts:
Video: The Importance of Market Cap
